Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Trelagliptin (formerly also known as SYR-472; trade name Zafatek) is a potent, highly selective, long-acting inhibitor of DPP-4 (dipeptidyl peptidase-4) that may have hypoglycemic effects. Takeda was developing it, and Japan had approved it for the management of type 2 diabetes (T2D). Trelagliptin has an advantage over other approved medications of the same class in that it can be given once a week rather than once daily as is typically the case.
Targets |
DPP-4 (IC50 = 4 nM)
|
---|---|
ln Vitro |
Dipeptidyl peptidase-4 (DPP-4) is one of the extensively studied novel targets for the type 2 diabetes mellitus (T2DM) strategy that inhibits the DPP-4 action in order to maintain the endogenous glucagon-like peptide (GLP)-1 activity[1].
Trelagliptin has a strong inhibitory effect on DPP-4 that is prepared from Caco-2 cells, with an IC50 value of 5.4 nM. Additionally, trelagliptin inhibits the plasma DPP-4 activity of rats, dogs, and humans with IC50 values of 4.2 nM, 6.2 nM, and 9.7 nM, respectively[2]. Trelagliptin exhibits >10,000-fold selectivity over DPP-2, DPP-8, DPP-9, PEP, and FAPα activities, and it is highly selective for DPP-4, with IC50 values >100,000 nM. Trelagliptin is approximately 4- and 12-fold more potent than sitagliptin and alogliptin in terms of DPP4 selectivity[2]. |
ln Vivo |
Trelagliptin (oral gavage; 7 mg/kg; single dose) inhibits DPP-4 activity >80% of the time even after 24 hours in dogs, demonstrating a sustained Parkinson's disease effect[1].
Trelagliptin (oral gavage; 3 mg/kg; single dose; 60 min prior to oral glucose) reduces the AUC0−120min of 19.3% in ob/ob mice when compared to the vehicle group, greatly improving the glucose tolerance capacity[3].
Trelagliptin (oral gavage; 10 mg/kg; once a week; 8 weeks) significantly lowered fasting blood glucose (FBG) levels; over the course of the treatment period, the average decrease was 16.8% lower than in the control group.Additionally, it raises insulin levels, which in ob/ob mice are raised by 1.7-fold in AUC0−120min[3].
|
Animal Protocol |
ICR ob/ob mice[3]
10 mg/kg Oral gavage; 10 mg/kg; once a week; 8 weeks |
References |
|
Molecular Formula |
C18H20FN5O2
|
---|---|
Molecular Weight |
357.38
|
Exact Mass |
357.16
|
Elemental Analysis |
C, 60.49; H, 5.64; F, 5.32; N, 19.60; O, 8.95
|
CAS # |
865759-25-7
|
Appearance |
Solid powder
|
SMILES |
CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCC[C@H](C3)N
|
InChi Key |
IWYJYHUNXVAVAA-OAHLLOKOSA-N
|
InChi Code |
InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1
|
Chemical Name |
2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile
|
Synonyms |
SYR 472; Trelagliptin; SYR-472; SYR472; trade name: Zafatek
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.7981 mL | 13.9907 mL | 27.9814 mL | |
5 mM | 0.5596 mL | 2.7981 mL | 5.5963 mL | |
10 mM | 0.2798 mL | 1.3991 mL | 2.7981 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03555591 | Completed | Drug: Trelagliptin | Type 2 Diabetes Mellitus | Takeda | May 1, 2016 | |
NCT02512068 | Completed | Drug: Trelagliptin 25 mg Drug: Placebo |
Type 2 Diabetes Mellitus | Takeda | August 7, 2015 | Phase 3 |
NCT04285983 | Completed | Drug: Trelagliptin | Type 2 Diabetes Mellitus | Takeda | March 1, 2020 | |
NCT03014479 | Completed | Drug: Trelagliptin Drug: Daily DPP-4 inhibitor |
Type 2 Diabetes | Takeda | February 18, 2017 | Phase 4 |
NCT02771093 | Completed | Drug: Trelagliptin Drug: Alogliptin |
Type 2 Diabetes Mellitus | Takeda | September 8, 2016 | Phase 4 |
Concentration response curves of DPP-4 inhibitory activities by trelagliptin, alogliptin and sitagliptin. PLoS One . 2016 Jun 21;11(6):e0157509. td> |
Double-reciprocal plot showing competitive inhibition of DPP-4 by trelagliptin. PLoS One . 2016 Jun 21;11(6):e0157509. td> |
Time course of the reaction of DPP-4 in the absence or presence of different concentrations of trelagliptin. PLoS One . 2016 Jun 21;11(6):e0157509. td> |
Time course of the recovery of DPP-4 activity following dissociation of trelagliptin from the preformed DPP-4-inhibitor complex. PLoS One . 2016 Jun 21;11(6):e0157509. td> |
Potential fluorine atom interactions in trelagliptin x-ray crystal structure. PLoS One . 2016 Jun 21;11(6):e0157509. td> |
Relationship between trelagliptin pharmacokinetics and pharmacodynamics in T2DM patients in phase 2 dose-ranging study. PLoS One . 2016 Jun 21;11(6):e0157509. td> |